Skip to main content
Top
Published in: Drug Safety 2/2013

Open Access 01-02-2013 | Original Research Article

Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen)

The Multinational Case-Population SALT Study

Authors: Sinem Ezgi Gulmez, Dominique Larrey, Georges-Philippe Pageaux, Severine Lignot, Régis Lassalle, Jérémy Jové, Angelo Gatta, P. Aiden McCormick, Harold J. Metselaar, Estela Monteiro, Douglas Thorburn, William Bernal, Irene Zouboulis-Vafiadis, Corinne de Vries, Susana Perez-Gutthann, Miriam Sturkenboom, Jacques Bénichou, Jean-Louis Montastruc, Yves Horsmans, Francesco Salvo, Fatima Hamoud, Sophie Micon, Cécile Droz-Perroteau, Patrick Blin, Nicholas Moore

Published in: Drug Safety | Issue 2/2013

Login to get access

Abstract

Background

Most NSAIDs are thought to be able to cause hepatic injury and acute liver failure (ALF), but the event rates of those leading to transplantation (ALFT) remain uncertain.

Objectives

The aim of the study was to estimate population event rates for NSAID-associated ALFT

Methods

This was a case-population study of ALFT in 57 eligible liver transplant centres in seven countries (France, Greece, Ireland, Italy, The Netherlands, Portugal and the UK). Cases were all adults registered from 2005 to 2007 for a liver transplant following ALFT without identified clinical aetiology, exposed to an NSAID or paracetamol (acetaminophen) within 30 days before the onset of clinical symptoms. NSAID and paracetamol population exposures were assessed using national sales data from Intercontinental Marketing Services (IMS). Risk was estimated as the rate of ALFT per million treatment-years (MTY).

Results

In the 52 participating centres, 9479 patients were registered for transplantation, with 600 for ALFT, 301 of whom, without clinical aetiology, had been exposed to a drug within 30 days. Of these 301 patients, 40 had been exposed to an NSAID and 192 to paracetamol (81 of whom were without overdose).
Event rates per MTY were 1.59 (95 % CI 1.1–2.2) for all NSAIDs pooled, 2.3 (95 % CI 1.2–3.9) for ibuprofen, 1.9 (95 % CI 0.8–3.7) for nimesulide, 1.6 (95 % CI 0.6–3.4) for diclofenac and 1.6 (95 % CI 0.3–4.5) for ketoprofen. For paracetamol, the event rate was 3.3 per MTY (95 % CI 2.6–4.1) without overdoses and 7.8 (95 % CI 6.8–9.0) including overdoses.

Conclusions

ALF leading to registration for transplantation after exposure to an NSAID was rare, with no major difference between NSAID. Non-overdose paracetamol-exposed liver failure was twice more common than NSAID-exposed liver failure.
Appendix
Available only for authorised users
Literature
1.
go back to reference Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76.PubMedCrossRef Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76.PubMedCrossRef
2.
go back to reference Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;196:407–18.PubMedCrossRef Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;196:407–18.PubMedCrossRef
4.
go back to reference Danan G, Trunet P, Bernuau J, Degott C, Babany G, Pessayre D, et al. Pirprofen-induced fulminant hepatitis. Gastroenterology. 1985;89(1):210–3.PubMed Danan G, Trunet P, Bernuau J, Degott C, Babany G, Pessayre D, et al. Pirprofen-induced fulminant hepatitis. Gastroenterology. 1985;89(1):210–3.PubMed
5.
go back to reference Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16(45):5651–61.PubMedCrossRef Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16(45):5651–61.PubMedCrossRef
6.
go back to reference Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003;327(7405):18–22.PubMedCrossRef Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ. 2003;327(7405):18–22.PubMedCrossRef
7.
go back to reference Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf. 2010;19(7):708–14.PubMedCrossRef Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf. 2010;19(7):708–14.PubMedCrossRef
8.
go back to reference Theophile H, Laporte JR, Moore N, Martin KL, Begaud B. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf. 2011;34(10):861–8.PubMedCrossRef Theophile H, Laporte JR, Moore N, Martin KL, Begaud B. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf. 2011;34(10):861–8.PubMedCrossRef
9.
go back to reference Gulmez SE, Lignot-Maleyran S, DeVries C, Sturkenboom M, Micon S, Hamoud F, et al. Administrative complexities for a European observational study despite directives harmonising requirements. Pharmacoepidemiol Drug Saf. 2012;21:851–6.PubMedCrossRef Gulmez SE, Lignot-Maleyran S, DeVries C, Sturkenboom M, Micon S, Hamoud F, et al. Administrative complexities for a European observational study despite directives harmonising requirements. Pharmacoepidemiol Drug Saf. 2012;21:851–6.PubMedCrossRef
11.
go back to reference O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439–45.PubMed O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439–45.PubMed
12.
go back to reference Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6(4):648–51.PubMedCrossRef Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6(4):648–51.PubMedCrossRef
13.
go back to reference Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol. 1990;11(2):272–6.PubMedCrossRef Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol. 1990;11(2):272–6.PubMedCrossRef
14.
go back to reference Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6.PubMedCrossRef Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6.PubMedCrossRef
15.
go back to reference Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30.PubMedCrossRef Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30.PubMedCrossRef
16.
go back to reference Danan G, Benichou C, Begaud B, Biour M, Couzigou P, Evreux JC, et al. Criteria of imputation of acute hepatitis to a drug: results of consensus meetings [in French]. Gastroenterol Clin Biol. 1987;11(8–9):581–5.PubMed Danan G, Benichou C, Begaud B, Biour M, Couzigou P, Evreux JC, et al. Criteria of imputation of acute hepatitis to a drug: results of consensus meetings [in French]. Gastroenterol Clin Biol. 1987;11(8–9):581–5.PubMed
17.
go back to reference Guidelines for ATC classification and DDD assignment. 4th ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2001. Guidelines for ATC classification and DDD assignment. 4th ed. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2001.
18.
go back to reference Fourrier-Reglat A, Cuong HM, Lassalle R, Depont F, Robinson P, Droz-Perroteau C, et al. Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort. Pharmacoepidemiol Drug Saf. 2010;19(5):474–81.PubMed Fourrier-Reglat A, Cuong HM, Lassalle R, Depont F, Robinson P, Droz-Perroteau C, et al. Concordance between prescriber- and patient-reported previous medical history and NSAID indication in the CADEUS cohort. Pharmacoepidemiol Drug Saf. 2010;19(5):474–81.PubMed
19.
go back to reference Fourrier-Reglat A, Lacoin L, Pariente A, Lassalle R, Robinson P, Droz-Perroteau C, et al. When patients report diseases that prescribers seem unaware of: discordance between patient and physician reporting of risk-related previous history in NSAID users from the CADEUS study. Clin Pharmacol Ther. 2010;88(5):668–75.PubMedCrossRef Fourrier-Reglat A, Lacoin L, Pariente A, Lassalle R, Robinson P, Droz-Perroteau C, et al. When patients report diseases that prescribers seem unaware of: discordance between patient and physician reporting of risk-related previous history in NSAID users from the CADEUS study. Clin Pharmacol Ther. 2010;88(5):668–75.PubMedCrossRef
20.
go back to reference Moore N, Pierfitte C, Pehourcq F, Lagnaoui R, Begaud B. Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects. Clin Pharmacol Ther. 2001;69(6):445–50.PubMedCrossRef Moore N, Pierfitte C, Pehourcq F, Lagnaoui R, Begaud B. Comparison of patient questionnaires, medical records, and plasma assays in assessing exposure to benzodiazepines in elderly subjects. Clin Pharmacol Ther. 2001;69(6):445–50.PubMedCrossRef
21.
go back to reference Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf. 2007;16(8):891–900.PubMedCrossRef Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf. 2007;16(8):891–900.PubMedCrossRef
22.
go back to reference Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, et al. The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf. 2007;16(5):571–80.PubMedCrossRef Depont F, Fourrier A, Merliere Y, Droz C, Amouretti M, Begaud B, et al. The CADEUS study: methods and logistics. Pharmacoepidemiol Drug Saf. 2007;16(5):571–80.PubMedCrossRef
23.
go back to reference Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–59.PubMedCrossRef Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–59.PubMedCrossRef
24.
go back to reference Maddur H, Chalasani N. Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep. 2011;13(1):65–71.PubMedCrossRef Maddur H, Chalasani N. Idiosyncratic drug-induced liver injury: a clinical update. Curr Gastroenterol Rep. 2011;13(1):65–71.PubMedCrossRef
25.
go back to reference Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis. 2007;11(3):563–75, vi–vii. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis. 2007;11(3):563–75, vi–vii.
26.
go back to reference Ponsoda X, Bort R, Jover R, Gomez-Lechon MJ, Castell JV. Molecular mechanism of diclofenac hepatotoxicity: association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol In Vitro. 1995;9(4):439–44.PubMedCrossRef Ponsoda X, Bort R, Jover R, Gomez-Lechon MJ, Castell JV. Molecular mechanism of diclofenac hepatotoxicity: association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol In Vitro. 1995;9(4):439–44.PubMedCrossRef
27.
go back to reference Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly. 2010;140:w13080.PubMed Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly. 2010;140:w13080.PubMed
28.
go back to reference Graham GG, Day RO, Graudins A, Mohamudally A. FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? Inflammopharmacology. 2010;18(2):47–55.PubMedCrossRef Graham GG, Day RO, Graudins A, Mohamudally A. FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? Inflammopharmacology. 2010;18(2):47–55.PubMedCrossRef
29.
go back to reference Guggenheimer J, Moore PA. The therapeutic applications of and risks associated with acetaminophen use: a review and update. J Am Dent Assoc. 2011;142(1):38–44.PubMed Guggenheimer J, Moore PA. The therapeutic applications of and risks associated with acetaminophen use: a review and update. J Am Dent Assoc. 2011;142(1):38–44.PubMed
30.
go back to reference Craig DG, Bates CM, Davidson JS, Martin KG, Hayes PC, Simpson KJ. Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol. 2011. Craig DG, Bates CM, Davidson JS, Martin KG, Hayes PC, Simpson KJ. Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol. 2011.
31.
go back to reference Sabate M, Ibanez L, Perez E, Vidal X, Buti M, Xiol X, et al. Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol. 2011;11:80.PubMedCrossRef Sabate M, Ibanez L, Perez E, Vidal X, Buti M, Xiol X, et al. Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol. 2011;11:80.PubMedCrossRef
32.
go back to reference Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–72.PubMedCrossRef Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–72.PubMedCrossRef
33.
go back to reference Andrade RJ, Lucena MI, Garcia-Escano MD, Camargo R. Severe idiosyncratic acute hepatic injury caused by paracetamol. J Hepatol. 1998;28(6):1078.PubMedCrossRef Andrade RJ, Lucena MI, Garcia-Escano MD, Camargo R. Severe idiosyncratic acute hepatic injury caused by paracetamol. J Hepatol. 1998;28(6):1078.PubMedCrossRef
35.
go back to reference Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther. 2000;7(2):99–114.PubMedCrossRef Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther. 2000;7(2):99–114.PubMedCrossRef
36.
37.
go back to reference Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137(3):856–64, 864.e1. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137(3):856–64, 864.e1.
38.
go back to reference Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother. 2009;43(4):761–6.PubMedCrossRef Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother. 2009;43(4):761–6.PubMedCrossRef
Metadata
Title
Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen)
The Multinational Case-Population SALT Study
Authors
Sinem Ezgi Gulmez
Dominique Larrey
Georges-Philippe Pageaux
Severine Lignot
Régis Lassalle
Jérémy Jové
Angelo Gatta
P. Aiden McCormick
Harold J. Metselaar
Estela Monteiro
Douglas Thorburn
William Bernal
Irene Zouboulis-Vafiadis
Corinne de Vries
Susana Perez-Gutthann
Miriam Sturkenboom
Jacques Bénichou
Jean-Louis Montastruc
Yves Horsmans
Francesco Salvo
Fatima Hamoud
Sophie Micon
Cécile Droz-Perroteau
Patrick Blin
Nicholas Moore
Publication date
01-02-2013
Publisher
Springer International Publishing AG
Published in
Drug Safety / Issue 2/2013
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-012-0013-7

Other articles of this Issue 2/2013

Drug Safety 2/2013 Go to the issue